<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35306032</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>05</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1874-1754</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>356</Volume>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
              <Day>01</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of cardiology</Title>
          <ISOAbbreviation>Int J Cardiol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>RIvaroxaban in mitral stenosis (RISE MS): A pilot randomized clinical trial.</ArticleTitle>
        <Pagination>
          <StartPage>83</StartPage>
          <EndPage>86</EndPage>
          <MedlinePgn>83-86</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijcard.2022.03.037</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0167-5273(22)00396-5</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND">Patients with moderate-to-severe mitral stenosis (MS) have bee excluded from all major randomized controlled trials (RCTs) comparing non-vitamin K antagonist oral anticoagulants (NOACs) with warfarin in patients with atrial fibrillation (AF).</AbstractText>
          <AbstractText Label="METHODS AND RESULTS">In this pilot RCT, 40 patients were randomized to rivaroxaban 20 mg daily or warfarin. No patients experienced symptomatic ischemic strokes and systemic embolic events (the primary composite study outcome) during a 12-month follow-up. No major bleeding was reported. During the follow-up, 18.2% of patients in both groups showed echocardiographic signs of increased thrombogenicity in the left atrial appendage. The rate of silent cerebral ischemia was 13.3% in the rivaroxaban group and 17.6% in the warfarin group at brain magnetic resonance imaging.</AbstractText>
          <AbstractText Label="CONCLUSION">Our results suggest acceptable efficacy and safety for rivaroxaban in patients with AF and moderate-to-severe MS and are encouraging for larger RCTs in this so far neglected setting (NCT03926156).</AbstractText>
          <CopyrightInformation>Copyright © 2022. Published by Elsevier B.V.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sadeghipour</LastName>
            <ForeName>Parham</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran; Clinical Trial Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pouraliakbar</LastName>
            <ForeName>Hamidreza</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Parsaee</LastName>
            <ForeName>Mozhgan</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shojaeifard</LastName>
            <ForeName>Maryam</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Farrashi</LastName>
            <ForeName>Melody</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Echocardiography Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>JamalKhani</LastName>
            <ForeName>Sepehr</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tashakori Beheshti</LastName>
            <ForeName>Ahmad</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Rostambeigi</LastName>
            <ForeName>Saman</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ebrahimi Meimand</LastName>
            <ForeName>Saeed</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Firouzi</LastName>
            <ForeName>Ata</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Peighambari</LastName>
            <ForeName>Mohammad Mehdi</ForeName>
            <Initials>MM</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alemzadeh-Ansari</LastName>
            <ForeName>Mohammad Javad</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haghjoo</LastName>
            <ForeName>Majid</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiac Electrophysiology Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Noohi</LastName>
            <ForeName>Feridoun</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Maleki</LastName>
            <ForeName>Majid</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Cardiovascular Intervention Research Center, Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>De Caterina</LastName>
            <ForeName>Raffaele</ForeName>
            <Initials>R</Initials>
            <AffiliationInfo>
              <Affiliation>University Cardiology Division, Pisa University Hospital, Pisa, Italy; Fondazione VillaSerena per la Ricerca, Città Sant'Angelo, Pescara, Italy. Electronic address: raffaele.decaterina@unipi.it.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <DataBankList CompleteYN="Y">
          <DataBank>
            <DataBankName>ClinicalTrials.gov</DataBankName>
            <AccessionNumberList>
              <AccessionNumber>NCT03926156</AccessionNumber>
            </AccessionNumberList>
          </DataBank>
        </DataBankList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016449">Randomized Controlled Trial</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>16</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Int J Cardiol</MedlineTA>
        <NlmUniqueID>8200291</NlmUniqueID>
        <ISSNLinking>0167-5273</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>5Q7ZVV76EI</RegistryNumber>
          <NameOfSubstance UI="D014859">Warfarin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9NDF7JZ4M3</RegistryNumber>
          <NameOfSubstance UI="D000069552">Rivaroxaban</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008946" MajorTopicYN="Y">Mitral Valve Stenosis</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000069552" MajorTopicYN="N">Rivaroxaban</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020521" MajorTopicYN="Y">Stroke</DescriptorName>
          <QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014859" MajorTopicYN="N">Warfarin</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Atrial fibrillation</Keyword>
        <Keyword MajorTopicYN="Y">Direct oral anticoagulants</Keyword>
        <Keyword MajorTopicYN="Y">Mitral stenosis</Keyword>
        <Keyword MajorTopicYN="Y">Non-vitamin K antagonist oral anticoagulants</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>14</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>21</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>20</Day>
          <Hour>20</Hour>
          <Minute>27</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35306032</ArticleId>
        <ArticleId IdType="doi">10.1016/j.ijcard.2022.03.037</ArticleId>
        <ArticleId IdType="pii">S0167-5273(22)00396-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
